Allegro chooses LégiaPark to develop its business
Top-level talent, an outstanding logistics location, and a dynamic ecosystem are the key factors that convinced Allegro to expand at LégiaPark in Liège..
/--/uploads/sites/4/2026/02/Allegro01.jpeg)
/--/uploads/sites/4/2026/02/Allegro02.jpeg)
The Flemish biotech company Allegro has chosen the LégiaPark facilities in Liège to develop its business, aimed to treat osteoarthritis in horses and humans.
Allegro is a biomedical company that develops revolutionary nanotechnology treatments for degenerative joint diseases. Founded in 2021, the biotech is about to reach a decisive milestone after several years of research and clinical trials. Allegro is launching the commercial production of Synoglide, an injectable product designed to treat osteoarthritis in horses.
“We will be producing syringes containing a new technology to fight osteoarthritis. It’s a huge innovation worldwide. These are gel particles suspended in a liquid. That’s a major difference compared with other products,” explains Lucas Decuypere, CEO of Allegro.
This production is intended in particular for the American pharmaceutical group American Regent, which will distribute the new treatment in the United States for the equine market.
/--/uploads/sites/4/2026/02/Allegro03.jpeg)
“I am extremely proud that we are launching production of our innovative product only four years after Allegro was founded. We plan to begin clinical trials in 2026, with the ambition of restoring mobility to the hundreds of millions of people worldwide who suffer from osteoarthritis,” adds Lucas Decuypere.
Allegro will focus on the clinical development of its hydrogel technology for human use under the name Hydrocelin. The company plans to launch a human feasibility study in the first half of 2026, to be followed by an international registration trial. Hydrocelin contains cross-linked particles designed to act like tiny shock absorbers in synovial fluid. Restoring the shock-absorbing capacity of synovial fluid aims to relieve pain and protect joint cartilage.
In Wallonia, we find top-level talent, an exceptional logistics location thanks to Liège Airport, and a dynamic ecosystem supported by Noshaq, as well as by the government and the Wallonia Export & Investment Agency. Everything is in place to develop innovative technology
The choice of Wallonia
Although the company first launched in Flanders in 2021, Lucas Decuypere made the strategic decision to transfer all Allegro activities to Wallonia, at the heart of a life sciences ecosystem located at LégiaPark in Liège.
“We could have chosen to outsource production. That might have been easier, but not better. Producing your own product and controlling the entire production chain is very valuable in this business. It is also the best way to create value both as a company and as a regional ecosystem,” he concludes.
